Fetch.ai's Innovation Lab has demonstrated a system where three AI agents autonomously manage a full blockchain transaction lifecycle on BNB Chain's testnet. One agent sends test BNB, another verifies the transaction's success, and a third monitors wallet activity for anomalies. This uses Fetch.ai's uAgents framework and Python coding, showcasing practical multi-agent blockchain interactions without financial risk. This development aligns with BNB Chain's AI roadmap, including SDK releases and standards like ERC-8004 and ERC-8183, aiming to enhance agent identity verification and payment processes on-chain.
The BNB Chain's new automated transaction workflow with uAgents is presented here alongside Pluang's market snapshot as of Sep 15, 2026 23:51 WIB. Among 50 major cryptocurrencies, only 8 rose while 41 fell. For example, ADA (Cardano) trades at Rp3.570 with a 4.08% decline and a typical hold time of 125 days, contrasting with ZIL (Zilliqa) at Rp50, down 4.05%, but held longer at 132 days. ETH (Ethereum) is priced at Rp42.844.587, down 3.93%, with a shorter hold time of 106 days and a more balanced buy/sell order activity compared to ADA and ZIL.
Uber Technologies reported a 25% year-over-year increase in gross bookings to $53.7 billion in Q1 2026, driven by growth in ride-hailing, delivery, grocery, retail, and membership services. CEO Dara Khosrowshahi's recent purchase of 141,000 shares wo...
Waystar Holding Corp, a healthcare software company valued at around $5.1 billion, saw its stock rise 8.6% to $27.05 following reports that it is evaluating strategic options, including a potential sale. Barclays set a new price target of $30, sugges...
MasterCraft Boat Holdings reported fiscal Q4 2026 adjusted earnings of $0.67 per share and revenue of $129.94 million, surpassing estimates. Revenue growth was driven by its Performance and Wake business and the Marine Products acquisition, which add...
Redwood Trust's CFO, Carillo Brooke, increased her stake by purchasing 26,065 shares, showing confidence despite a major shareholder urging the board to consider selling the company. The stock trades at a 33% discount to its GAAP book value due to ri...
BioMarin Pharmaceutical received a price target upgrade to $97 from BMO Capital, reflecting about 50% upside from current levels. This follows positive Phase 3 trial results for VOXZOGO®, a treatment for hypochondroplasia, showing significant growth ...
